JP2023517312A - ヒト免疫不全ウイルスの複製阻害剤 - Google Patents

ヒト免疫不全ウイルスの複製阻害剤 Download PDF

Info

Publication number
JP2023517312A
JP2023517312A JP2022553214A JP2022553214A JP2023517312A JP 2023517312 A JP2023517312 A JP 2023517312A JP 2022553214 A JP2022553214 A JP 2022553214A JP 2022553214 A JP2022553214 A JP 2022553214A JP 2023517312 A JP2023517312 A JP 2023517312A
Authority
JP
Japan
Prior art keywords
mmol
stirred
added
reaction
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553214A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021176367A5 (https=
JP2023517312A5 (https=
Inventor
エリック、ピー、ギリス
クリスティアナ、イワグウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2023517312A publication Critical patent/JP2023517312A/ja
Publication of JPWO2021176367A5 publication Critical patent/JPWO2021176367A5/ja
Publication of JP2023517312A5 publication Critical patent/JP2023517312A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022553214A 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2023517312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985946P 2020-03-06 2020-03-06
US62/985,946 2020-03-06
PCT/IB2021/051765 WO2021176367A1 (en) 2020-03-06 2021-03-03 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2023517312A true JP2023517312A (ja) 2023-04-25
JPWO2021176367A5 JPWO2021176367A5 (https=) 2024-03-13
JP2023517312A5 JP2023517312A5 (https=) 2024-03-13

Family

ID=74870854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553214A Pending JP2023517312A (ja) 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤

Country Status (4)

Country Link
US (1) US20230106880A1 (https=)
EP (1) EP4114527A1 (https=)
JP (1) JP2023517312A (https=)
WO (1) WO2021176367A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510038A (ja) * 2013-03-01 2016-04-04 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのアミド化合物
JP2017538713A (ja) * 2014-12-23 2017-12-28 ギリアード サイエンシーズ， インコーポレイテッド 多環式カルバモイルピリドン化合物およびそれらの薬学的使用
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
EP3060554A1 (en) 2013-10-24 2016-08-31 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112017022605A2 (pt) 2015-04-23 2018-07-17 Viiv Healthcare Uk No 5 Ltd ?composto, composição, e, método para tratamento de infecção por hiv?.
CN107995910A (zh) 2015-04-23 2018-05-04 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510038A (ja) * 2013-03-01 2016-04-04 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのアミド化合物
JP2017538713A (ja) * 2014-12-23 2017-12-28 ギリアード サイエンシーズ， インコーポレイテッド 多環式カルバモイルピリドン化合物およびそれらの薬学的使用
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
US20230106880A1 (en) 2023-04-06
EP4114527A1 (en) 2023-01-11
WO2021176367A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
CN114245795B (zh) 作为人类免疫缺陷病毒复制抑制剂的吡啶并[2,3-d]嘧啶衍生物
JP2023517312A (ja) ヒト免疫不全ウイルスの複製阻害剤
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
US20220105096A1 (en) Inhibitors of human immunodeficiency virus replication
JP7799620B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
WO2020058844A1 (en) Inhibitors of human immunodeficiency virus replication
EP4038064B1 (en) N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
JP2023517043A (ja) ヒト免疫不全ウイルスの複製阻害剤
US20230013823A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022551691A (ja) ヒト免疫不全ウイルスの複製阻害剤
RU2804033C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR122024005456A2 (pt) Compostos inibidores de replicação do vírus da imunodeficiência humana, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos no tratamento de infecção por hiv
CA3173866A1 (en) Inhibitors of human immunodeficiency virus replication
EA044806B1 (ru) Ингибиторы репликации вируса иммунодефицита человека

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250905